Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.
作者信息
Inaba T, Tyndale R E, Mahon W A
出版信息
Br J Clin Pharmacol. 1986 Aug;22(2):199-200. doi: 10.1111/j.1365-2125.1986.tb05251.x.
Abstract
摘要
相似文献
1
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.奎尼丁：体内对司巴丁和异喹胍氧化有强效抑制作用。
Br J Clin Pharmacol. 1986 Aug;22(2):199-200. doi: 10.1111/j.1365-2125.1986.tb05251.x.
2
3
In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.关于人肝脏中司巴丁/异喹胍单加氧酶对奎尼丁氧化作用的体外证据。
Drug Metab Dispos. 1988 Jan-Feb;16(1):15-7.
4
Polymorphic oxidation of debrisoquine and sparteine.
Prog Clin Biol Res. 1986;214:157-67.
5
Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.药物氧化的去甲丙咪嗪/鹰爪豆碱型遗传多态性的酶学基础。对遗传缺陷的体内表型携带者肝脏微粒体中布呋洛尔1'-羟化作用的表征。
Biochem Pharmacol. 1987 Dec 1;36(23):4145-52. doi: 10.1016/0006-2952(87)90573-9.
6
A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.一种通过抑制研究鉴定为司巴丁-异喹胍单加氧酶的人细胞色素P-450。
Can J Physiol Pharmacol. 1984 Jul;62(7):860-2. doi: 10.1139/y84-144.
7
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.鹰爪豆碱和异喹胍的多态性氧化：相关药物遗传学实体。
Clin Pharmacol Ther. 1982 Feb;31(2):184-6. doi: 10.1038/clpt.1982.29.
8
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.司巴丁N-氧化缺陷与异喹胍4-羟化的药物遗传学共变。
Eur J Clin Pharmacol. 1980 Feb;17(2):153-5. doi: 10.1007/BF00562624.
9
Deficient metabolism of debrisoquine and sparteine.异喹胍和鹰爪豆碱代谢缺陷。
Clin Pharmacol Ther. 1980 Apr;27(4):547-9. doi: 10.1038/clpt.1980.77.
10
Comparative pharmacogenetics of sparteine and debrisoquine.鹰爪豆碱和异喹胍的比较药物遗传学
Clin Pharmacol Ther. 1983 Mar;33(3):394-9. doi: 10.1038/clpt.1983.51.
引用本文的文献
1
A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.接受美沙酮维持治疗患者的细胞色素P450 2D6基因型与表型之间的不一致性。
Br J Clin Pharmacol. 2003 Aug;56(2):220-4. doi: 10.1046/j.1365-2125.2003.01851.x.
2
Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.在具有三个或更多功能性CYP2D6基因的受试者中，奎尼丁对异喹胍羟基化的抑制作用。
Br J Clin Pharmacol. 2000 Feb;49(2):180-4. doi: 10.1046/j.1365-2125.2000.00120.x.
3
Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.美沙酮对人细胞色素P450 2D6（CYP2D6）的抑制作用。
Br J Clin Pharmacol. 1993 Jan;35(1):30-4. doi: 10.1111/j.1365-2125.1993.tb05666.x.
4
Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine.酮康唑对S-美芬妥英和异喹胍多态性4-羟化反应的影响。
Br J Clin Pharmacol. 1989 Aug;28(2):161-5. doi: 10.1111/j.1365-2125.1989.tb05409.x.
5
Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver.奎尼丁对人肝脏微粒体组分右美沙芬O-脱甲基酶活性的影响。
Br J Clin Pharmacol. 1989 Jul;28(1):29-36. doi: 10.1111/j.1365-2125.1989.tb03502.x.
6
Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.普罗帕酮与低剂量奎尼丁之间的遗传决定相互作用：活性代谢物在调节药物净效应中的作用。
Br J Clin Pharmacol. 1989 Apr;27(4):435-44. doi: 10.1111/j.1365-2125.1989.tb05391.x.
7
Clinical pharmacokinetic considerations in the elderly. An update.老年人的临床药代动力学考量。最新进展。
Clin Pharmacokinet. 1989 Oct;17(4):236-63. doi: 10.2165/00003088-198917040-00003.
8
Relevance of genetic polymorphism in drug metabolism in the development of new drugs.药物代谢中的基因多态性在新药研发中的相关性。
Eur J Clin Pharmacol. 1989;36(6):551-4. doi: 10.1007/BF00637734.
9
A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.奎尼丁对人体中司巴丁氧化体内抑制作用的剂量效应研究。
Br J Clin Pharmacol. 1990 Mar;29(3):299-304. doi: 10.1111/j.1365-2125.1990.tb03639.x.
10
Drug interactions in hypertensive patients. Pharmacokinetic, pharmacodynamic and genetic considerations.高血压患者的药物相互作用。药代动力学、药效学及遗传学考量
Clin Pharmacokinet. 1990 Apr;18(4):295-317. doi: 10.2165/00003088-199018040-00003.
本文引用的文献
1
Comparative pharmacogenetics of sparteine and debrisoquine.鹰爪豆碱和异喹胍的比较药物遗传学
Clin Pharmacol Ther. 1983 Mar;33(3):394-9. doi: 10.1038/clpt.1983.51.
2
Polymorphic drug oxidation in humans.人类的多态性药物氧化
Fed Proc. 1984 May 15;43(8):2298-302.
3
Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.β-肾上腺素受体拮抗剂及其他心血管药物对人肝脏中司巴丁氧化的竞争性抑制作用。
Life Sci. 1984 Jan 2;34(1):73-80. doi: 10.1016/0024-3205(84)90332-1.
4
In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.
Drug Metab Dispos. 1985 Jul-Aug;13(4):443-8.
5
Oxidation phenotype and the metabolism and action of beta-blockers.
Klin Wochenschr. 1985 Apr 1;63(7):285-92. doi: 10.1007/BF01731972.
Zotero 插件